Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.
2.

Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.

Sinha AA, Quast BJ, Wilson MJ, Fernandes ET, Reddy PK, Ewing SL, Gleason DF.

Cancer. 2002 Jun 15;94(12):3141-9.

3.

High placenta-specific 1/low prostate-specific antigen expression pattern in high-grade prostate adenocarcinoma.

Ghods R, Ghahremani MH, Madjd Z, Asgari M, Abolhasani M, Tavasoli S, Mahmoudi AR, Darzi M, Pasalar P, Jeddi-Tehrani M, Zarnani AH.

Cancer Immunol Immunother. 2014 Dec;63(12):1319-27. doi: 10.1007/s00262-014-1594-z. Epub 2014 Sep 4.

PMID:
25186610
4.

The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma.

Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufman RP Jr, Ross JS.

Cancer. 1997 Aug 15;80(4):753-63.

PMID:
9264360
5.
6.

Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature review.

Qiu YQ, Leuschner I, Braun PM.

Asian J Androl. 2008 Nov;10(6):855-63. doi: 10.1111/j.1745-7262.2008.00428.x.

7.

Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.

Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, Klee GG, Tindall DJ, Bostwick DG.

Urology. 1997 Jun;49(6):857-62.

PMID:
9187691
8.

Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen.

Chan TY, Mikolajczyk SD, Lecksell K, Shue MJ, Rittenhouse HG, Partin AW, Epstein JI.

Urology. 2003 Jul;62(1):177-81.

PMID:
12837462
9.

E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.

Rubin MA, Mucci NR, Figurski J, Fecko A, Pienta KJ, Day ML.

Hum Pathol. 2001 Jul;32(7):690-7.

PMID:
11486167
10.

Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study.

Hampel OZ, Kattan MW, Yang G, Haidacher SJ, Saleh GY, Thompson TC, Wheeler TM, Marcelli M.

J Urol. 1998 Jun;159(6):2220-5.

PMID:
9598573
12.

Combined application of RT-PCR and immunohistochemistry on paraffin embedded sentinel lymph nodes of prostate cancer patients.

Haas CJ, Wagner T, Wawroschek F, Arnholdt H.

Pathol Res Pract. 2005;200(11-12):763-70.

PMID:
15792118
13.
14.

Biological aggressiveness evaluation in prostate carcinomas:immunohistochemical analysis of PCNA and p53 in a series of Gleason 6 (3+3) adenocarcinomas.

Cappello F, Palma A, Martorana A, Rappa F, Cabibi D, Barresi E, Melloni D, Farina F, Aragona F.

Eur J Histochem. 2003;47(2):129-32.

PMID:
12777208
15.

Evidence of surfactant protein A and D expression decrement and their localizations in human prostate adenocarcinomas.

Kankavi O, Baykara M, Eren Karanis MI, Bassorgun CI, Ergin H, Ciftcioglu MA.

Ren Fail. 2014 Mar;36(2):258-65. doi: 10.3109/0886022X.2013.846831. Epub 2013 Oct 29.

PMID:
24168624
16.

Cathepsin B in angiogenesis of human prostate: an immunohistochemical and immunoelectron microscopic analysis.

Sinha AA, Gleason DF, Staley NA, Wilson MJ, Sameni M, Sloane BF.

Anat Rec. 1995 Mar;241(3):353-62.

PMID:
7538734
17.

Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.

Stumm L, Burkhardt L, Steurer S, Simon R, Adam M, Becker A, Sauter G, Minner S, Schlomm T, Sirma H, Michl U.

J Clin Pathol. 2013 Jul;66(7):563-8. doi: 10.1136/jclinpath-2012-201335. Epub 2013 Apr 4.

PMID:
23559350
18.

Evaluation of alpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers.

Gumulec J, Masarik M, Krizkova S, Hlavna M, Babula P, Hrabec R, Rovny A, Masarikova M, Sochor J, Adam V, Eckschlager T, Kizek R.

Neoplasma. 2012;59(2):191-201.

PMID:
22248277
19.

[Relation of serum prostate-specific antigen and the Gleason grade in patients with prostatic carcinoma].

Zivković S, Velicković L, Kostov M, Stojanović N.

Vojnosanit Pregl. 2003 Jul-Aug;60(4):449-54. Serbian.

PMID:
12958804
20.

Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues.

Petraki CD, Gregorakis AK, Papanastasiou PA, Karavana VN, Luo LY, Diamandis EP.

Prostate Cancer Prostatic Dis. 2003;6(3):223-7.

PMID:
12970725

Supplemental Content

Support Center